Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eniluracil + 5-FU + Leucovorin vs Capecitabine in Metastatic Breast Cancer
NCT01231802Phase 2Unknown
- Sponsor
- Adherex Technologies
- Start
- Apr 2011
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of eniluracil in breast cancer (2 arms), sponsored by Adherex Technologies. Primary endpoint: Progression-free survival at 7.5 months. Status: unknown.
02
Drugs
eniluracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01231802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231802.